EMPIL–DOC Act
The source supplies the latest action, but no lifecycle stage.
Latest action (12 May 2020): Referred to the House Committee on Energy and Commerce.
What this bill does
This bill, called the EMPIL-DOC Act, would authorize a program for the U.S. to award grants for developing health technologies, especially those related to COVID-19. The technologies could include artificial intelligence, respiratory devices, and diagnostic tests. The program would emphasize using technology, personalized medicine, and data to combat the virus.
Funding for this program would require a matching contribution from the Israeli government. The legislation specifies that appropriations of $4,000,000 would be authorized for each fiscal year from 2021 through 2023. This program could either build on an existing U.S.-Israel agreement or establish a new one.
The bill was introduced in the House of Representatives in May 2020 by Representative Chris Pappas and others. It has been referred to the House Committee on Energy and Commerce. The bill's status is currently "Introduced," meaning it has not yet been passed by either chamber of Congress or signed into law.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
Expanding Medical Partnerships with Israel to Lessen Dependence on China Act or the EMPIL-DOC Act
This bill authorizes a bilateral grant program with Israel to develop health technologies, with an emphasis on the use of technology, personalized medicine, and data in relation to COVID-19 (i.e., coronavirus disease 2019). Technologies to be developed through this program include, among others, artificial intelligence, respiratory assist devices, and diagnostic tests.
In addition, the program conditions funding on a matching contribution from the government of Israel.
Timeline
12 May 2020
Referred to the House Committee on Energy and Commerce.
Common questions
- What does H.R. 6829 do?
- This bill, called the EMPIL-DOC Act, would authorize a program for the U.S. to award grants for developing health technologies, especially those related to COVID-19. The technologies could include artificial intelligence, respiratory devices, and diagnostic tests. The program would emphasize using technology, personalized medicine, and data to combat the virus. Funding for this program would require a matching contribution from the Israeli government. The legislation specifies that appropriations of $4,000,000 would be authorized for each fiscal year from 2021 through 2023. This program could either build on an existing U.S.-Israel agreement or establish a new one. The bill was introduced in the House of Representatives in May 2020 by Representative Chris Pappas and others. It has been referred to the House Committee on Energy and Commerce. The bill's status is currently "Introduced," meaning it has not yet been passed by either chamber of Congress or signed into law.
- Has H.R. 6829 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 6829. Check the latest action and official source below.
- Who sponsored H.R. 6829?
- H.R. 6829 was sponsored by Rep. Pappas, Chris [D-NH-1] (D-NH), with 242 cosponsors.
- What's the latest action on H.R. 6829?
- Referred to the House Committee on Energy and Commerce. (12 May 2020).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
More bills from Rep. Pappas, Chris [D-NH-1]
Baby Brent’s Bill
Investing in State Energy Act of 2026
Turn the Tide Act
Apprenticeship Program National Scorecard Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.